194 related articles for article (PubMed ID: 30567881)
1. Kinetics of Cyclophosphamide Metabolism in Humans, Dogs, Cats, and Mice and Relationship to Cytotoxic Activity and Pharmacokinetics.
Ramirez DA; Collins KP; Aradi AE; Conger KA; Gustafson DL
Drug Metab Dispos; 2019 Mar; 47(3):257-268. PubMed ID: 30567881
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.
de Jonge ME; Huitema AD; van Dam SM; Rodenhuis S; Beijnen JH
Ther Drug Monit; 2005 Dec; 27(6):756-65. PubMed ID: 16306851
[TBL] [Abstract][Full Text] [Related]
3. Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes.
de Jonge ME; Huitema AD; van Dam SM; Rodenhuis S; Beijnen JH
Anticancer Drugs; 2005 Mar; 16(3):331-6. PubMed ID: 15711186
[TBL] [Abstract][Full Text] [Related]
4. [Activity and induction of CYP2B, CYP2C, and CYP3A in tissues of cyclophosphane-sensitive and resistant neoplasms and the liver of neoplasm-carrying mice].
Grishanov AIu; Kaledin VI; Zueva TV; Nekhoroshkova EK; Nikolin VP; Liakhovich VV
Biomed Khim; 2003; 49(1):27-34. PubMed ID: 14569871
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450-mediated hepatic metabolism of new fluorescent substrates in cats and dogs.
van Beusekom CD; Schipper L; Fink-Gremmels J
J Vet Pharmacol Ther; 2010 Dec; 33(6):519-27. PubMed ID: 21062303
[TBL] [Abstract][Full Text] [Related]
6. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes.
Ren S; Yang JS; Kalhorn TF; Slattery JT
Cancer Res; 1997 Oct; 57(19):4229-35. PubMed ID: 9331082
[TBL] [Abstract][Full Text] [Related]
7. Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes.
Griskevicius L; Yasar U; Sandberg M; Hidestrand M; Eliasson E; Tybring G; Hassan M; Dahl ML
Eur J Clin Pharmacol; 2003 Jun; 59(2):103-9. PubMed ID: 12684728
[TBL] [Abstract][Full Text] [Related]
8. Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide.
May-Manke A; Kroemer H; Hempel G; Bohnenstengel F; Hohenlöchter B; Blaschke G; Boos J
Cancer Chemother Pharmacol; 1999; 44(4):327-34. PubMed ID: 10447581
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics of cyclophosphamide.
de Jonge ME; Huitema AD; Rodenhuis S; Beijnen JH
Clin Pharmacokinet; 2005; 44(11):1135-64. PubMed ID: 16231966
[TBL] [Abstract][Full Text] [Related]
10. Initial characterization of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, SR 4233, WIN 59075).
Riley RJ; Hemingway SA; Graham MA; Workman P
Biochem Pharmacol; 1993 Mar; 45(5):1065-77. PubMed ID: 8461036
[TBL] [Abstract][Full Text] [Related]
11. Identification of the human cytochrome P450s responsible for the in vitro metabolism of a leukotriene B4 receptor antagonist, CP-195,543.
Khojasteh-Bakht SC; Rossulek MI; Fouda HG; Prakash C
Xenobiotica; 2003 Dec; 33(12):1201-10. PubMed ID: 14742142
[TBL] [Abstract][Full Text] [Related]
12. A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide.
Huitema AD; Mathôt RA; Tibben MM; Rodenhuis S; Beijnen JH
J Pharmacokinet Pharmacodyn; 2001 Jun; 28(3):211-30. PubMed ID: 11468938
[TBL] [Abstract][Full Text] [Related]
13. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
Roy P; Waxman DJ
Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
[TBL] [Abstract][Full Text] [Related]
14. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles.
Roy P; Yu LJ; Crespi CL; Waxman DJ
Drug Metab Dispos; 1999 Jun; 27(6):655-66. PubMed ID: 10348794
[TBL] [Abstract][Full Text] [Related]
15. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation.
Chang TK; Yu L; Goldstein JA; Waxman DJ
Pharmacogenetics; 1997 Jun; 7(3):211-21. PubMed ID: 9241661
[TBL] [Abstract][Full Text] [Related]
16. Fractionated administration of high-dose cyclophosphamide: influence on dose-dependent changes in pharmacokinetics and metabolism.
Busse D; Busch FW; Schweizer E; Bohnenstengel F; Eichelbaum M; Fischer P; Schumacher K; Aulitzky WE; Kroemer HK
Cancer Chemother Pharmacol; 1999; 43(3):263-8. PubMed ID: 9923558
[TBL] [Abstract][Full Text] [Related]
17. The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes.
Helsby NA; Yong M; van Kan M; de Zoysa JR; Burns KE
Br J Clin Pharmacol; 2019 Sep; 85(9):1925-1934. PubMed ID: 31218720
[TBL] [Abstract][Full Text] [Related]
18. CYP2C and CYP2B Mediated Metabolic Activation of Retrorsine in Cyp3a Knockout Mice.
Pang X; Tang C; Kong F; Chen M; Chen X
Curr Drug Metab; 2020; 21(13):1040-1051. PubMed ID: 33267758
[TBL] [Abstract][Full Text] [Related]
19. Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome p450 reductase null mouse.
Pass GJ; Carrie D; Boylan M; Lorimore S; Wright E; Houston B; Henderson CJ; Wolf CR
Cancer Res; 2005 May; 65(10):4211-7. PubMed ID: 15899812
[TBL] [Abstract][Full Text] [Related]
20. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.
Anderson LW; Chen TL; Colvin OM; Grochow LB; Collins JM; Kennedy MJ; Strong JM
Clin Cancer Res; 1996 Sep; 2(9):1481-7. PubMed ID: 9816324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
